Skip to main content

Table 3 Baseline clinical characteristics of DR-TB patients stratified by lost to follow-up status, University of Gondar Comprehensive Specialized Hospital, September 2010–December 2017, (N = 332)

From: Incidence and predictors of lost to follow-up among drug-resistant tuberculosis patients at University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia: a retrospective follow-up study

Variable

Frequency (%)

Lost to follow-up status

Eventa (n = 36)

Censoredb (n = 296)

BMI

 < 18.5

221 (71.99)

25

186

 > =18.50

86 (18.01)

8

78

Functional status

 Working

78 (23.49)

7

71

 Ambulatory

225 (67.77)

29

196

 Bedridden

29 (8.73)

0

29

Registration Group

 New

41 (12.35)

4

37

 Relapse

45 (13.55)

5

40

 Return after lost to follow-up

2 (0.60)

1

1

 Failure

241 (72.60)

26

215

 outcome not assigned

3 (0.90)

0

3

No of previous TB treatment

 < 2

112 (33.74)

11

101

 > =2

218 (65.66)

25

193

 Not recorded

2 (0.60)

0

2

Site of tuberculosis

 Pulmonary

306 (92.17)

31

275

 Extra Pulmonaryc

26 (7.83)

5

21

Lung complication

 No complication

275 (82.83)

29

246

 Pneumonia

39 (11.75)

5

34

 Pneumothorax

5 (1.51)

0

5

 Corpulmonale

9 (2.71)

1

8

 Bronchiectasis

4 (1.20)

1

3

Co-morbidity

 No

277 (83.43)

30

247

 Yesd

55 (16.57)

6

49

HIV co-infection

 No

246 (74.10)

27

219

 Yes

84 (25.30)

9

75

 Unknown

2 (0.60)

0

2

Base line sputum smear result

 Negative

48 (14.46)

6

42

 Positive

258 (77.71)

27

231

 Not recorded

26 (7.83)

3

23

Baseline Culture result

 Positive

180 (54.22)

15

165

 Negative

71 (21.38)

12

59

 Not recorded

81 (24.40)

9

72

Culture converted among baseline Culture result positive

 Yes

159 (88.33)

9

150

 No

21 (11.67)

6

15

DR-TB type

 RR-TB

147 (44.28)

17

130

 MDR-TB

168 (50.60)

18

150

 Clinically diagnosed

17 (5.12)

1

16

  1. Eventa in this study was patients lost during follow-up; Censoredb was either cured, completed, death, transfer out, still on treatment
  2. cLymph node, vertebral, bone, testicular, and skin
  3. dDiabetes Mellitus, Hypertension, Bronchial Asthma, CKD, and Cardiac diseases